Solid Biosciences Inc. SLDB R2KR3KPHARMA
Company Overview
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -40.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -40.57% |
Stock Price Performance
| 1 Year: | +53.44% |
| 6 Months: | +51.85% |
| 3 Months: | +52.99% |
| 1 Month: | +17.68% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)61.24 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SLDB Solid Biosciences Inc. R2KR3KPHARMA | 10.25 | -5.54 | $1.10B | 0.00% | -90.02% | -57.37% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -14.11M | -11.89M | -13.70M | -15.16M | -15.97M | -18.18M | -19.15M | -22.39M | -30.30M | -26.97M | -29.72M | -32.33M | -26.86M | -18.97M | -21.23M | -16.89M | -18.68M | -18.03M | -25.37M | -25.38M | -21.13M | -32.03M | -26.84M | -23.11M | -26.86M | -27.79M | -35.18M | -40.05M | -41.69M | -48.06M | -57.31M | -57.38M |
| Net Income | -12.81M | -11.31M | -13.51M | -14.49M | -15.88M | -17.98M | -19.02M | -21.92M | -29.58M | -26.52M | -29.25M | - | -26.69M | -18.99M | -21.25M | -16.90M | -18.70M | -17.98M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.17 | -2.40 | -3.37 | -3.33 | -2.71 | -1.54 | -1.25 | -1.05 | -0.64 | -0.61 | -0.79 | -0.59 | -0.42 | -0.48 | -0.52 | -0.38 |
| R&D Expense | 8.73M | 8.61M | 10.62M | - | 11.93M | 13.59M | 14.68M | - | 23.27M | 21.61M | 22.79M | - | 19.66M | 13.45M | 16.05M | 14.21M | 15.51M | 14.43M | 19.95M | 23.18M | 14.01M | 24.63M | 19.78M | 16.70M | 18.87M | 19.46M | 27.33M | 30.91M | 32.41M | 38.86M | 46.14M | 44.27M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 13.62M | 8.09M | - | - | - |
| Operating Income | -25.58M | -54.86M | -75.69M | -119.32M | -88.41M | -72.25M | -106.45M | -104.25M | -129.73M | -179.21M |
| Net Income | -21.54M | -52.12M | -74.80M | -117.22M | - | - | - | - | - | - |
| Diluted EPS | - | - | - | - | -25.50 | -10.14 | -10.10 | -4.83 | -3.06 | -1.99 |
| R&D Expense | 20.12M | 39.91M | 57.97M | 94.74M | 64.88M | 58.74M | 78.42M | 76.56M | 96.43M | 140.32M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 76.19M | 139.60M | 103.47M | 171.17M | 232.38M | 260.25M | 164.94M | 188.66M | 232.54M |
| Total Equity | -37.89M | -59.26M | 125.18M | 80.05M | 132.09M | 208.21M | 211.67M | 126.48M | 137.25M | 180.01M |
| Cash & Equivalents | 7.68M | 52.08M | 86.37M | 76.04M | 154.74M | 119.14M | 155.38M | 74.02M | 80.23M | 59.90M |
| Total Liabilities | - | 11.27M | 14.41M | 23.42M | 39.08M | 24.17M | 48.59M | 38.46M | 51.42M | 52.53M |
| Current Liabilities | - | 11.27M | 12.48M | 18.28M | 24.48M | 23.60M | 22.51M | 14.52M | 30.26M | 33.47M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.12M | -43.22M | -70.20M | -92.71M | -56.60M | - | -97.98M | -94.18M | -100.01M | -156.29M |
| Investing Cash Flow | -4.05M | 10.45M | -26.76M | 24.52M | 6.60M | - | 59.16M | 9.69M | -16.09M | -58.45M |
| Financing Cash Flow | 3.42M | 77.08M | 131.51M | 57.88M | 128.70M | - | 74.83M | 3.12M | 122.44M | 194.45M |
| Capital Expenditure | -392.00K | -2.28M | -7.78M | -4.39M | -899.00K | - | -3.02M | -1.51M | -654.00K | -1.15M |
| Free Cash Flow | -20.51M | -45.50M | -77.97M | -97.10M | -57.50M | - | -100.99M | -95.69M | -100.67M | -157.44M |
| Net Change in Cash | - | - | - | - | - | - | 36.01M | -81.37M | 6.34M | -20.30M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | -530.5% | -1,315.2% | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| ROE % | 56.9% | 88.0% | -59.8% | -146.4% | - | - | - | - | - | - |
| ROCE % | - | -84.5% | -59.5% | -140.1% | -60.3% | -34.6% | -44.8% | -69.3% | -81.9% | -90.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 11.23% | 12.04M | $117.59M |
| 2 | Perceptive Advisors Llc | 11.10% | 11.91M | $116.33M |
| 3 | Bain Capital Life Sciences Investors, LLC | 9.15% | 9.81M | $95.83M |
| 4 | Siren, L.L.C. | 7.17% | 7.69M | $75.14M |
| 5 | Blackrock Inc. | 6.47% | 6.93M | $67.75M |
| 6 | FMR, LLC | 6.41% | 6.88M | $67.18M |
| 7 | Armistice Capital, LLC | 3.99% | 4.28M | $41.80M |
| 8 | State Street Corporation | 3.89% | 4.18M | $40.79M |
| 9 | Jupiter Topco LLC | 3.77% | 4.04M | $39.51M |
| 10 | Vanguard Capital Management LLC | 3.74% | 4.01M | $39.18M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SLDB
Solid Biosciences Stock Price Forecast. Should You Buy SLDB? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE1hWm1tdkk5dGxUTExUQnkyOE4zODhDaHZPTkN3Wmk5N25wWFhXV1RUdU1iS0pSM0p4WXZvVmRRMXhyN2E1WGVybA?oc=5" target="_blank">Solid Biosciences Stock Price Forecast. Should You Buy SLDB?</a> …
Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPRXRsY05VWUN4a0FqaThncC0tQXIzWV9VOFpIaHpMa2RqZUtkSTZxa2ZlazBiNTFNWVNUOEMzRFFNMnpENG1OWF9YQk5mVjNnMlJIOGZnY1VkaUZMU0pJVkU5bnd5dGQ3a3pmckNvY01JNUthUVVlLXl5ak5jX3ZCWTRWVXo2bGY3S2xNT1…
SLDB Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1Yak52elQxbjhJbjhKeFpKWVVZYm5uNlZOSVMwSzk4enhsRHdKTTNTU0RzOWxfQ2hxWmRFUi1rZEJEVEtNQXRFUDNHbFFKMHZJSTZfMm5uTFJqWjRLRk5oWHB5ZHQ4dUFZS2x5N3RGc1FUcXdBWGs0R0R3?oc=5" target="_blank">SLD…
Solid Biosciences Insiders Sell US$823k Of Stock, Possibly Signalling Caution - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxOdkhlTFgwOW1fXzRGajlNaHZmUTRieGl5VXh2Tkh1Q29WZ1BRQnNwblFhc2RrZFJ3aW44V2dlYlY4c0FVQl9aUUxOWmlyT2paNENlTTlqZENCSE9fcGQ3ckk4bTVWVG9OZGs2NnR4R3lEaUowVFVTaUpQWEF1N05feGpUakhackhuZkp5SG…
Solid Biosciences LLC (NASDAQ: SLDB) Share Price, SLDB Stock News, SLDB Share Price & Updates - Kalkine
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE5nRFVrX3o2VUk0VGZNSnNONnQybTBiWXJOc1o3dVRQM212bmpUbmpMTGEzREtxblpWUW5PMElNMl9vSXA5Y3QzaG5DZGxLZ1VlM3JTOWt3?oc=5" target="_blank">Solid Biosciences LLC (NASDAQ: SLDB) Share Price, S…
$SLDB stock is down 11% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQUWZQRjFVRGdrYXBMZU5OQ1FuSHZyOWo0ajJpaXJQVjROXzUxbng2OHFlY0wyYWFaM0dYeDNXYkY3N2JmZ2JXMzRIU1Y2QWxyb2VuQUUyMjZvSjBRSG9ZaWhzdmNTNzdwU2V6QXZNOE1kNFJaWVk4bDVpZUc2NkpkQlhXZWV2eFBmeTBwUH…
SLDB — Frequently Asked Questions
What is the current share price of Solid Biosciences Inc. (SLDB)?
As of 2026-09-07 16:24 PDT, Solid Biosciences Inc. (SLDB) trades at $10.25 on NasdaqGS. Its 52-week range is $3.93 to $11.15.
What is the market capitalisation of SLDB?
Solid Biosciences Inc. (SLDB) has a market capitalisation of $1.10B on NasdaqGS.
What is the P/E ratio of SLDB?
SLDB trades at a trailing price-to-earnings (P/E) ratio of -5.54. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.21.
What is the return on equity (ROE) of SLDB?
SLDB has a return on equity (ROE) of -57.37%. Its return on capital employed (ROCE) is -90.02%.
Is SLDB a good stock to buy?
This page provides a data-driven analysis of Solid Biosciences Inc. (SLDB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.